Positive overall survival (OS) data from the Phase III TALAPRO-2 trial could position Pfizer Inc. Inc.’s Talzenna (talazoparib) and Xtandi (enzalutamide) for broader use in metastatic prostate cancer.
Key Takeaways
- Pfizer’s PARP inhibitor Talzenna with Xtandi showed an overall survival benefit in patients with metastatic castration resistant prostate cancer regardless of mutation status.
The company announced on 10 October that the combination of the poly ADP-ribose polymerase (PARP) inhibitor Talzenna with the commonly...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?